drugset / Trial / NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

NCT06568094

Phase 1/2 Recruiting 100 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Timeline

Start
2024-09-25
Primary completion
2026-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule
Subject Darolutamide Other / unclassified
Subject Docetaxel Small molecule
Subject HRS-1167 Unknown
Subject HRS-5041 Other / unclassified
Subject HRS-6208 Unknown
Subject Prednisone Other / unclassified
Subject SHR2554 Small molecule

Indications